Bevacizumab Against Recurrent Retinal Detachment

• Status: Completed
• Trial end date: 2019-11-11
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Eyes with rhegmatogenous retinal detachment

Exclusion Criteria:

• Presence of PVR

• Need for a procedure other than primary PPV such as a scleral buckle with or without PPV, laser retinopexy, or pneumatic retinopexy.

• Recent intravitreal injection of an anti-VEGF agent less than 3 months prior

• Secondary retinal detachment repair

• Use of silicone oil as tamponade agent

• Patients less than 18 years of age

• Pregnancy

• Known allergy or contraindication to intravitreal bevacizumab